@article{22cb3ebacc46423dac2d9eb9f0621e3c,
title = "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial",
author = "Kristian Reich and Papp, {Kim A.} and Andrew Blauvelt and Langley, {Richard G.} and April Armstrong and Warren, {Richard B.} and Gordon, {Kenneth B.} and Merola, {Joseph F.} and Yukari Okubo and Cynthia Madden and Maggie Wang and Christopher Cioffi and Veerle Vanvoorden and Mark Lebwohl",
note = "Funding Information: We thank the patients, the investigators, and their teams who took part in this study. We also acknowledge Susanne Wiegratz (UCB Pharma, Monheim, Germany) for publication coordination, Eva Cullen (UCB Pharma, Brussels, Belgium) for critical review, and Louise Whiteley and Emma Phillips (Costello Medical, UK) for medical writing and editorial assistance based on the authors' input and direction, and the UCB Pharma BE VIVID clinical team. This study was funded by UCB Pharma. RBW is supported by the Manchester National Institute for Health Research Biomedical Research Centre. Support for third-party writing assistance for this article was funded by UCB Pharma in accordance with Good Publication Practice 3 guidelines . Funding Information: We thank the patients, the investigators, and their teams who took part in this study. We also acknowledge Susanne Wiegratz (UCB Pharma, Monheim, Germany) for publication coordination, Eva Cullen (UCB Pharma, Brussels, Belgium) for critical review, and Louise Whiteley and Emma Phillips (Costello Medical, UK) for medical writing and editorial assistance based on the authors' input and direction, and the UCB Pharma BE VIVID clinical team. This study was funded by UCB Pharma. RBW is supported by the Manchester National Institute for Health Research Biomedical Research Centre. Support for third-party writing assistance for this article was funded by UCB Pharma in accordance with Good Publication Practice 3 guidelines. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",
year = "2021",
month = feb,
day = "6",
doi = "10.1016/S0140-6736(21)00125-2",
language = "English",
volume = "397",
pages = "487--498",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10273",
}